Skip to content

PTSD pharmacotherapy

TL;DR — Sertraline and paroxetine are the two FDA-approved medications for PTSD; fluoxetine and venlafaxine are commonly evaluated off-label, and guidelines generally prefer trauma-focused psychotherapy when available (Rothbaum 2025, PMID 40308104). Medication meta-analyses find benefits for some agents but smaller and less durable evidence than first-line psychotherapies (Williams 2022, PMID 35234292) (Mavranezouli 2020, PMID 32063234). Drug evidence must remain PTSD-specific: pooled anxiety-disorder response is not a PTSD effect. Prazosin is symptom-targeted and treated separately because its large veteran re-test was null (Raskind 2018, PMID 29414272).

Evidence hierarchy

Positive acute symptom change should be separated from remission, function, relapse prevention and discontinuation. Head-to-head drug comparisons are sparse: the Cochrane review covers 66 RCTs (7,442 participants) but reports mainly drug-versus-placebo contrasts (Williams 2022, PMID 35234292), and the largest randomized comparison against psychotherapy found no difference in 24-week CAPS change between sertraline plus enhanced medication management, prolonged exposure plus placebo, and prolonged exposure plus sertraline in 223 combat veterans (P=.81 for slope difference) (Rauch 2019, PMID 30516797). Benzodiazepines are the clearest case of a widely used class without supporting efficacy evidence in PTSD (18 studies, 5,236 participants) (Guina 2015, PMID 26164054).

SSRIs and SNRI

Sertraline and paroxetine have regulatory trials and approval; venlafaxine has RCT evidence but is not FDA-approved for PTSD. In the Cochrane synthesis, SSRIs improved treatment response versus placebo (RR 0.66, 95% CI 0.59–0.74; 8 studies, 1,078 participants), corresponding to 58% improving on SSRIs against 35% on placebo, at moderate-certainty evidence; mirtazapine (RR 0.45, 95% CI 0.22–0.94; 1 study, 26 participants) and amitriptyline (RR 0.60, 95% CI 0.38–0.96; 1 study, 40 participants) also improved symptoms but on low-certainty single-trial evidence, and antipsychotics showed no evidence of benefit for the number improving (RR 0.51, 95% CI 0.16–1.67; 2 studies, 43 participants) at very low certainty. Withdrawal due to adverse events was higher on SSRIs than placebo (RR 1.41, 95% CI 1.07–1.87; 14 studies, 2,399 participants), though the absolute proportion was 9% (Williams 2022, PMID 35234292). Class labels should therefore not imply equal evidence for every molecule: a single 26-person trial and an 8-study SSRI pool are not the same evidential object.

Augmentation

Antipsychotic, anticonvulsant and adrenergic augmentation studies are heterogeneous and mostly small. A placebo-controlled pilot of ziprasidone added to SSRIs found no significant difference from placebo on CAPS or any other outcome, with the sample too small to be decisive either way (Hamner 2019, PMID 30640209). The largest augmentation programme is brexpiprazole plus sertraline, tested in a phase 3 trial at 86 US sites against sertraline plus placebo (Davis 2025, PMID 39693081); as of a 2026 review the combination had not been approved, and its rejection is cited as an illustration of how often mechanistically plausible PTSD candidates fail late (Obi 2026, PMID 41792251). A negative or small augmentation trial cannot be rescued by a broader anxiety-disorder class effect.

Harms

Sexual dysfunction, gastrointestinal effects, activation, sedation, blood-pressure effects and discontinuation symptoms must be balanced against absolute benefit. Trial abstracts often under-report longer-term harms.

Comorbidity

Treating comorbid depression may change depressive symptoms without establishing a PTSD-specific effect. Depression remains cross-linked to its own condition; SUD treatment is integrated or coordinated rather than assumed to resolve after PTSD treatment (Coventry 2020, PMID 32813696).

Shared decisions

Preferences, prior response, pregnancy, overdose risk, interactions, adherence burden and access to psychotherapy shape choice. This page is evidence synthesis, not prescribing advice.

Emerging agents

Ketamine, cannabinoids and other agents remain investigational for core PTSD, and PTSD-specific controlled trials — not depression findings — are what count (Stein 2021, PMID 33517752). For ketamine the PTSD-specific evidence is now directly contradictory. A 30-participant randomized trial of six ketamine (0.5 mg/kg) versus midazolam infusions over two weeks found CAPS-5 total 11.88 points lower with ketamine at week 2 (SE 3.96; d=1.13, 95% CI 0.36–1.91), with 67% versus 20% responders and a median 27.5 days to loss of response (Feder 2021, PMID 33397139). A multi-site trial of 158 veterans and service members randomized to placebo, 0.2 mg/kg or 0.5 mg/kg ketamine over eight infusions found no significant group-by-time interaction on PCL-5 or CAPS-5, with the antidepressant effect on MADRS preserved (Abdallah 2022, PMID 35046508). The two differ in population, dose schedule and comparator, and the discrepancy is unresolved. For cannabinoids, the broadest synthesis covers medicinal cannabinoids across mental disorders rather than a PTSD-specific efficacy estimate (Black 2019, PMID 31672337). A newer mechanism has produced a positive PTSD-specific signal: in a 65-participant phase 2 randomized trial with no psychotherapy component, the neuroplastogen TSND-201 (methylone) improved CAPS-5 more than placebo (least-squares mean difference 9.64; 90% CI −16.48 to −2.80; P=.01) (Jones 2026, PMID 41706459, NCT05741710).

Quantitative anchors

Measure Estimate Population/method Source
FDA-approved PTSD drugs sertraline; paroxetine US regulatory status (Rothbaum 2025, PMID 40308104)
Adult psychotherapy NMA 90 trials; n=6,560 Psychotherapy-first comparative context (Mavranezouli 2020, PMID 32063234)
Prazosin re-test n=304 Nightmares/sleep primary outcomes null (Raskind 2018, PMID 29414272)
Complex-event component NMA mixed interventions Comorbidity scope explicit (Coventry 2020, PMID 32813696)
SSRI vs placebo response RR 0.66 (95% CI 0.59–0.74); 58% vs 35% 8 studies; n=1,078; moderate certainty (Williams 2022, PMID 35234292)
SSRI withdrawal for adverse events RR 1.41 (95% CI 1.07–1.87); absolute 9% 14 studies; n=2,399 (Williams 2022, PMID 35234292)
Antipsychotics, number improved RR 0.51 (95% CI 0.16–1.67) 2 studies; n=43; very low certainty (Williams 2022, PMID 35234292)
Sertraline vs PE vs combination no difference in 24-week CAPS slope (P=.81) 223 combat veterans (Rauch 2019, PMID 30516797)
Repeated ketamine vs midazolam CAPS-5 −11.88 points (d=1.13, 95% CI 0.36–1.91) n=30; chronic PTSD (Feder 2021, PMID 33397139)
Repeated ketamine, multi-site no significant group-by-time effect on PCL-5/CAPS-5 n=158 veterans/service members (Abdallah 2022, PMID 35046508)
TSND-201 (methylone) vs placebo CAPS-5 LS mean difference 9.64 (90% CI −16.48 to −2.80) n=65; phase 2; no psychotherapy (Jones 2026, PMID 41706459)
Benzodiazepines no evidence of efficacy for PTSD 18 studies; n=5,236 (Guina 2015, PMID 26164054)

Evidence ledger

The ledger lists the live-retrieved records used to bound this page. Inclusion does not make every record equally probative; design, population and comparator remain decisive.

PMID Year Evidence contribution Scope caution
40308104 2025 An Update on Psychotherapy for the Treatment of PTSD. PTSD-specific record; inspect design and population
35234292 2022 Pharmacotherapy for post traumatic stress disorder (PTSD). PTSD-specific record; inspect design and population
26164054 2015 Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis. Synthesis: preserve included-population and certainty limits
38647566 2024 Efficacy and acceptability of music therapy for post-traumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials. Synthesis: preserve included-population and certainty limits
39693081 2025 Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder: A Phase 3 Randomized Clinical Trial. PTSD-specific record; inspect design and population
34992738 2021 Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. Synthesis: preserve included-population and certainty limits
34708874 2022 MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis. Synthesis: preserve included-population and certainty limits
31672337 2019 Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Synthesis: preserve included-population and certainty limits
33397139 2021 A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. PTSD-specific record; inspect design and population
31693083 2020 Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder Symptoms: A Randomized Clinical Trial. PTSD-specific record; inspect design and population
10761678 2000 Psychosocial treatment of posttraumatic stress disorder. PTSD-specific record; inspect design and population
25644881 2015 Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Synthesis: preserve included-population and certainty limits
27890743 2017 Considering future pharmacotherapy for PTSD. PTSD-specific record; inspect design and population
32813696 2020 Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis. Synthesis: preserve included-population and certainty limits
32063234 2020 Psychological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Synthesis: preserve included-population and certainty limits
32284821 2020 Psychological therapies for post-traumatic stress disorder in adults: systematic review and meta-analysis. Synthesis: preserve included-population and certainty limits
26574151 2016 Psychological treatments for adults with posttraumatic stress disorder: A systematic review and meta-analysis. Synthesis: preserve included-population and certainty limits
29414272 2018 Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. PTSD-specific record; inspect design and population
12562588 2003 Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. PTSD-specific record; inspect design and population
17069768 2007 A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. PTSD-specific record; inspect design and population
33517752 2021 Ketamine for PTSD: Well, Isn't That Special. PTSD-specific record; inspect design and population
38795401 2024 Pharmacotherapy for sleep disturbances in post-traumatic stress disorder (PTSD): A network meta-analysis. Synthesis: preserve included-population and certainty limits
23842024 2013 Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. Synthesis: preserve included-population and certainty limits
39061119 2024 Psychotherapeutic and pharmacological agents for post-traumatic stress disorder with sleep disorder: network meta-analysis. Synthesis: preserve included-population and certainty limits
40243149 2025 Protocol MelatoSom-Kids-PTSD: sleep disturbances in children and adolescents with post-traumatic stress disorder (PTSD) - a randomized double-blind placebo-controlled trial to investigate the efficacy of paediatric prolonged-release melatonin. PTSD-specific record; inspect design and population
39828080 2025 Factors impacting prazosin efficacy for nightmares and insomnia in PTSD patients - a systematic review and meta-regression analysis. Synthesis: preserve included-population and certainty limits
30516797 2019 Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial. PTSD-specific record; inspect design and population
30640209 2019 Ziprasidone Augmentation of SSRI Antidepressants in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Pilot Study of Augmentation Therapy. Pilot; underpowered for a negative conclusion
35046508 2022 Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. PTSD-specific record; null primary outcome
41706459 2026 Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial. Phase 2; sponsor-employed authors; 90% CIs
41792251 2026 Investigational drugs in PTSD. Narrative review of pipeline; not an efficacy estimate

Interpretation guardrails

  • Trauma exposure, post-traumatic symptoms, acute stress disorder, DSM-5 PTSD, ICD-11 PTSD and ICD-11 complex PTSD are not interchangeable populations.
  • A mixed-anxiety or transdiagnostic estimate is labelled as such; only a source’s PTSD stratum can be treated as a PTSD effect.
  • Comorbid depression is measured separately and cross-linked to the depression condition; it is not absorbed into PTSD.
  • Waitlist, treatment-as-usual, attention control and active treatment answer different causal questions.
  • Registration, statistical significance and diagnostic loss do not respectively prove completion, clinical importance or functional recovery.
  • This page synthesizes research and does not provide individual medical advice.

Minimum extraction frame for studies on this topic

Field What must be retained Why it changes interpretation
Diagnostic system DSM version, ICD version, full/subthreshold Case mix is not interchangeable
Diagnostic method Structured interview, clinician judgment, self-report cutoff Screening is not diagnosis
Index trauma Type, timing, repetition, direct/indirect/occupational Conditional risk and phenotype differ
Population Civilian, veteran, refugee, child/adolescent, mixed Transportability is empirical
Baseline severity Mean, SD, range and exclusion threshold Ceiling and floor effects alter change
CPTSD status ITQ/ICD-11 definition and DSO score Complexity cannot be inferred from trauma count
Comorbidity Depression, GAD, SUD, pain, TBI measured separately Shared symptoms can distort effects
Comparator Waitlist, usual care, attention, active treatment The estimand changes with comparator
Treatment dose Sessions offered/attended, duration, homework Assignment is not exposure
Outcome Symptoms, diagnosis, response, function, sleep Outcomes are not interchangeable
Time point End point and prespecified follow-up windows Acute benefit may not persist
Missing data Denominator, reasons, imputation and estimand Attrition can bias rank and magnitude
Adverse events Definitions, ascertainment and arm-level counts Absence of reporting is not absence of harm
Therapist/context Training, fidelity, allegiance, setting Delivery is part of the intervention
Funding/conflicts Sponsor role and analytic independence Especially material for proprietary packages

Claims this page does not make

  • It does not infer PTSD from trauma exposure alone.
  • It does not treat a self-report cutoff as equivalent to a structured diagnosis.
  • It does not convert a pooled anxiety-disorder effect into a PTSD effect.
  • It does not convert a depression outcome in a comorbid sample into a PTSD outcome.
  • It does not infer superiority from a statistically significant within-group change.
  • It does not infer equivalence from a non-significant between-group test.
  • It does not infer effectiveness from trial registration or mechanistic plausibility.
  • It does not assume military, civilian, refugee and pediatric estimates transport unchanged.
  • It does not average conflicting estimates that use different definitions.
  • It does not treat lack of adverse-event reporting as evidence of safety.

Evidence-updating triggers

Trigger Required response
New diagnostic revision Recalculate which populations prior estimates represent
New head-to-head RCT Compare against active treatment, not only waitlist
New individual-participant synthesis Revisit effect modifiers and transportability
Registry status change Verify results and linked publication before changing conclusions
Guideline update Separate evidence review from panel recommendation
Regulatory decision Record decision date and source; do not infer from efficacy papers
Safety signal Re-extract denominator, ascertainment and exposure time by arm
Contradictory replication Display estimates side by side; do not average definitions

Evidence updates should preserve the prior estimate and explain why the new study changes—or does not change—the inference.

Open questions

  • Which medication effects persist beyond acute trials after discontinuation? (Williams 2022, PMID 35234292)
  • Can biomarkers or symptom profiles predict medication-versus-psychotherapy benefit? (Mavranezouli 2020, PMID 32063234)
  • Which augmentation strategies have PTSD-specific benefit under adequately blinded conditions? (Ma 2024, PMID 38647566)

References

  1. Rothbaum BO, et al. An Update on Psychotherapy for the Treatment of PTSD. Am J Psychiatry. 2025;182(5):424-437. PMID 40308104
  2. Williams T, et al. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2022;3(3):CD002795. PMID 35234292
  3. Guina J, et al. Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis. J Psychiatr Pract. 2015;21(4):281-303. PMID 26164054
  4. Ma YM, et al. Efficacy and acceptability of music therapy for post-traumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials. Eur J Psychotraumatol. 2024;15(1):2342739. PMID 38647566
  5. Davis LL, et al. Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder: A Phase 3 Randomized Clinical Trial. JAMA Psychiatry. 2025;82(3):218-227. PMID 39693081
  6. Hoskins MD, et al. Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. Eur J Psychotraumatol. 2021;12(1):1802920. PMID 34992738
  7. Smith KW, et al. MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis. J Clin Pharmacol. 2022;62(4):463-471. PMID 34708874
  8. Black N, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995-1010. PMID 31672337
  9. Feder A, et al. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry. 2021;178(2):193-202. PMID 33397139
  10. Rae Olmsted KL, et al. Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder Symptoms: A Randomized Clinical Trial. JAMA Psychiatry. 2020;77(2):130-138. PMID 31693083
  11. Foa EB Psychosocial treatment of posttraumatic stress disorder. J Clin Psychiatry. 2000;61 Suppl 5:43-8; discussion 49-51. PMID 10761678
  12. Hoskins M, et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry. 2015;206(2):93-100. PMID 25644881
  13. Friedman MJ, et al. Considering future pharmacotherapy for PTSD. Neurosci Lett. 2017;649:181-185. PMID 27890743
  14. Coventry PA, et al. Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis. PLoS Med. 2020;17(8):e1003262. PMID 32813696
  15. Mavranezouli I, et al. Psychological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med. 2020;50(4):542-555. PMID 32063234
  16. Lewis C, et al. Psychological therapies for post-traumatic stress disorder in adults: systematic review and meta-analysis. Eur J Psychotraumatol. 2020;11(1):1729633. PMID 32284821
  17. Cusack K, et al. Psychological treatments for adults with posttraumatic stress disorder: A systematic review and meta-analysis. Clin Psychol Rev. 2016;43:128-41. PMID 26574151
  18. Raskind MA, et al. Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. N Engl J Med. 2018;378(6):507-517. PMID 29414272
  19. Raskind MA, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(2):371-3. PMID 12562588
  20. Raskind MA, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007;61(8):928-34. PMID 17069768
  21. Stein MB, et al. Ketamine for PTSD: Well, Isn't That Special. Am J Psychiatry. 2021;178(2):116-118. PMID 33517752
  22. Lappas AS, et al. Pharmacotherapy for sleep disturbances in post-traumatic stress disorder (PTSD): A network meta-analysis. Sleep Med. 2024;119:467-479. PMID 38795401
  23. Watts BV, et al. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry. 2013;74(6):e541-50. PMID 23842024
  24. Huang CY, et al. Psychotherapeutic and pharmacological agents for post-traumatic stress disorder with sleep disorder: network meta-analysis. Ann Med. 2024;56(1):2381696. PMID 39061119
  25. Rolling J, et al. Protocol MelatoSom-Kids-PTSD: sleep disturbances in children and adolescents with post-traumatic stress disorder (PTSD) - a randomized double-blind placebo-controlled trial to investigate the efficacy of paediatric prolonged-release melatonin. Eur J Psychotraumatol. 2025;16(1):2474375. PMID 40243149
  26. Mendes TP, et al. Factors impacting prazosin efficacy for nightmares and insomnia in PTSD patients - a systematic review and meta-regression analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111253. PMID 39828080
  27. Rauch SAM, et al. Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(2):117-126. PMID 30516797
  28. Hamner MB, et al. Ziprasidone Augmentation of SSRI Antidepressants in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Pilot Study of Augmentation Therapy. J Clin Psychopharmacol. 2019;39(2):153-157. PMID 30640209
  29. Abdallah CG, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022;47(8):1574-1581. PMID 35046508
  30. Jones A, et al. Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial. JAMA Psychiatry. 2026;83(5):469-477. PMID 41706459
  31. Obi T, Ressler KJ. Investigational drugs in PTSD. Neuropsychopharmacology. 2026;51(7):1147-1160. PMID 41792251